mr-guided high intensity focused ultrasound (hifu) on pediatric solid tumors

Conditions: Relapsed Pediatric Solid Tumors; Refractory Pediatric Solid Tumors; Rhabdomyosarcoma; Ewing Sarcoma; Osteosarcoma; Neuroblastoma; Wilms Tumor; Hepatic Tumor; Germ Cell Tumor; Desmoid Tumor

Summary: the purpose of this study is to determine if magnetic resonance guided high intensity focused ultrasound ablative therapy is safe and feasible for children, adolescents, and young adults with refractory or relapsed solid tumors.

magnetic resonance (mr)-guided high intensity focused ultrasound (hifu) is an innovative technique that allows for non-invasive thermal ablation of tissue. advantages over conventional local tumor control such as surgery, radiation, or radiofrequency are that mr-hifu is completely non-invasive, non-ionizing, and enables ablation of large tumor volumes with avoidance of adjacent tissue injury. this study will evaluate the safety and feasibility of mr-hifu ablative therapy in children, adolescents, and young adults with refractory or relapsed solid tumors that are located in bone or soft tissue in close proximity to bone. patients ≤ 30 years of age with refractory or relapsed solid tumors with measurable target lesions that are located in bone or soft tissue in close proximity to bone are eligible. tolerability will be defined during the 14 days following mr-hifu ablation. patients will continue to be followed for tumor response and secondary outcomes for up to one year post ablation treatment.

Eligibility criteria:
inclusion criteria: age: ≤ 30 years of age. diagnosis: histologically confirmed malignant solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, ewing's sarcoma family of tumors, osteosarcoma, neuroblastoma, wilms' tumor, hepatic tumors, germ cell tumors, and desmoid tumors. tumor location: target lesion(s) must be located in bone or soft tissue in close proximity to bone. target lesions must be reachable within the normal safety margins of hifu as specified in the instructions for use. target lesion(s): radiographically evaluable or measurable solid tumor target lesion(s). therapeutic options: malignant tumor: the patient's cancer must have relapsed after or failed to respond to frontline curative therapy and there must not be other potentially curative treatment options available. curative therapy may include surgery, radiation therapy, chemotherapy, or any combination of these modalities. prior therapy: patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering on this study. no limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry. myelosuppressive chemotherapy: the last dose of all myelosuppressive anticancer drugs must be at least 3 weeks prior to study entry. immunotherapy: the last dose of immunotherapy (monoclonal antibody or vaccine) must be at least 4 weeks prior to study entry. biologic (anti-cancer agent): the last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry. radiation therapy: the last dose of radiation to more than 25 % of marrow containing bones (pelvis, spine, skull) must be at least 4 weeks prior to study entry. the last dose of all other local palliative (limited port) radiation must be at least 2 weeks prior to study entry. stem cell transplantation. at least 2 months post-autologous stem cell transplant or at least 3 months post-allogeneic transplant and recovered from toxicities without evidence of graft versus host disease and on stable doses of immunosuppressive medications if required. growth factors. the last dose of colony stimulating factors, such as filgrastim, sargramostim, and erythropoietin, must be at least 1 week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be at least 2 weeks prior to study entry. concurrent therapies: no other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted during hifu treatment and post treatment follow up for tolerability (see section 3.3). performance status: patients \> 16 years old must have a karnofsky performance level ≥ 50%, and children ≤ 16 years old must have a lansky performance level ≥ 50% (see appendix i). patients who are unable to walk because of paralysis or motor weakness, but who are up in a wheelchair will be considered ambulatory for the purpose of calculating the performance score. * hematologic function: 1. peripheral absolute neutrophil count (anc) of ≥750/µl 2. platelet count ≥75,000/µl (may receive transfusions) * renal function: age-adjusted normal serum creatinine or a creatinine clearance ≥60 ml/min/1.73 m2. * adequate pulmonary function: defined as no dyspnea at rest, and a pulse oximetry \>94% on room air if there is clinical indication for determination. * normal pt, ptt and inr \< 1.5 x uln (including patients on prophylactic anticoagulation) exclusion criteria: clinically significant unrelated systemic illness, such as serious infections, hepatic, renal or other organ dysfunction, which in the judgment of the principal or associate investigator would compromise the patient's ability to tolerate the general anesthetic required for the procedure. implant or prosthesis or scar tissue within the path of the hifu beam. target \<1 cm from nerve plexus, spinal canal, bladder, bowel target in contact with hollow viscera lesion in the skull inability to undergo mri and/or contraindication for mri inability to tolerate stationary position during hifu patients currently receiving other anticancer agents. patients currently receiving other investigational agents.

Keywords: relapsed pediatric solid tumors refractory pediatric solid tumors high intensity focused ultrasound rhabdomyosarcoma ewing's sarcoma osteosarcoma neuroblastoma wilms' tumor hepatic tumors germ cell tumors desmoid tumor